[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidad de Murcia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":279},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,49,75,102,128,152,172,198,218,234,258],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100648133","bacterial-diversity-study-using-16s-rrna-sequencing-of-periodontal-samples-from-patients-with-orthodontic-retainers-100648133",false,"NCT07718061","Bacterial Diversity Study Using 16S rRNA Sequencing of Periodontal Samples From Patients With Orthodontic Retainers","Ortho-Perio","Inclusion Criteria:\n\n* Treatment involving both dental arches\n* Permanent dentition with at least 24 teeth\n* Treatment duration longer than 12 months\n* Treatment using the Versatile MBT system with a 0.022-inch slot\n\nExclusion Criteria:\n\n* Patients with systemic disease or taking medications that may affect periodontal health\n* Inadequate restorations or active carious lesions\n* iodontal disease\n* Plaque index greater than 20% before placement of the retainer or during the study\n* Use of oral antiseptics within the previous 6 months or during the study period\n* Use of antibiotics within the previous 14 days or during the study period\n* Smokers\n* Pregnant or breastfeeding women\n* Presence of open gingival embrasures, crowding, or dental malposition in the mandibular anterior region after orthodontic treatment","ALL","18 Years","40 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","After completion of orthodontic treatment, a retention phase is required to prevent relapse of tooth malposition. Fixed retention in the mandibular anterior region is commonly used. This type of retainer is bonded to the lingual surfaces of the canines and incisors and may hinder oral hygiene, thereby promoting bacterial plaque accumulation and gingival inflammation.\n\nCurrently, probably due to the increasing use of clear aligner therapy, clear removable Essix-type retainers are becoming more widely used. Since these retainers can be removed by the patient, they may facilitate oral hygiene. However, studies assessing gingival health and the composition of the subgingival microbiota in patients wearing orthodontic retainers remain scarce.\n\nTherefore, the aim of this study will be to assess the composition of the gingival sulcus microbiota and gingival health in patients wearing fixed or removable orthodontic retainers.\n\nTen adult patients who have completed orthodontic treatment will be recruited and divided into two groups:\n\n1. Fixed retention group.\n2. Removable retention group.\n\nPeriodontal parameters will be assessed, and bacterial plaque samples will be collected from the gingival sulcus at five time points:\n\nT0: Bracket removal and dental scaling appointment. Periodontal parameters will be assessed, and plaque samples will be collected before bracket debonding and dental scaling.\n\nT1: Retainer placement appointment, three days after T0. Periodontal parameters will be assessed, and plaque samples will be collected before retainer placement.\n\nT2: One month after retainer placement.\n\nT3: Three months after retainer placement.\n\nT4: Six months after retainer placement.",[27,28,29,30,31],"Fixed Orthodontic Retainer","Orthodontic Appliances, Removable","Orthodontic Appliance Complication","Gingivitis","Periodontal Diseases",[33,34,30,35],"Orthodontic retainer","Periodontal health","Microbiota","RECRUITING","2026-07-27",{"date":39,"type":40},"2026-07-28","ACTUAL",{"date":42,"type":40},"2026-01-12",{"date":44,"type":21},"2027-07",{"name":46,"class":47},"Universidad de Murcia","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100635052","effectiveness-of-tdcs-in-paediatric-amblyopia-100635052","NCT07547670","Effectiveness of tDCS in Paediatric Amblyopia.","tDCS","Inclusion Criteria:\n\n* Children aged 4-14 years.\n* Strabismic amblyopia resistant to patching (PEDIG criteria).\n* Anisometropic amblyopia resistant to patching (PEDIG criteria).\n\nExclusion Criteria:\n\n* Ocular pathology.\n* Nystagmus.\n* Mental disability.\n* Cognitive delay.\n* Neurological problems incompatible with treatment.\n* Pacemakers.\n* Intracranial electrodes.\n* Implanted defibrillators.\n* Cranial pathologies.\n* Cranial lesions.\n* Withdrawal will occur upon adverse events, protocol deviation, refusal, or loss to follow-up.","4 Years","14 Years",{"count":59,"type":21},100,[24],"The goal of this randomized, double-blind clinical trial is to determine whether transcranial direct current stimulation (tDCS) can effectively and safely improve vision in children aged 4-14 years with strabismic or anisometropic amblyopia that has not responded to conventional patching therapy.\n\nThe main questions it aims to answer are:\n\nDoes tDCS produce significant and sustained improvements in visual acuity, contrast sensitivity, and stereopsis in children with amblyopia?\n\nIs tDCS a safe, well-tolerated, and faster alternative or complementary treatment compared with standard occlusion therapy?\n\nDoes tDCS induce functional and structural changes in the visual cortex associated with increased neuroplasticity, including modulation of GABAergic activity?\n\nIf there is a comparison group:\n\nResearchers will compare active tDCS with sham (placebo) stimulation to see if active treatment leads to greater visual recovery and cortical changes than placebo.\n\nParticipants will:\n\nReceive several sessions of active or sham tDCS using low-intensity electrical stimulation applied to visual brain areas.\n\nUndergo standard visual assessments, including visual acuity, contrast sensitivity, and stereopsis.\n\nComplete neurophysiological and neuroimaging evaluations (EEG, pattern visual evoked potentials, and functional MRI).\n\nProvide biochemical measures related to GABA levels.\n\nThis study aims to validate tDCS as a non-invasive, child-friendly, and effective therapy that may overcome the limitations of patching and support its inclusion in paediatric clinical practice.",[63,64,65,66],"Amblyopia","Amblyopia Strabismic","Visual Acuity","Stereoscopic Vision",[54,68],"Ambyopia",{"date":39,"type":40},{"date":71,"type":40},"2026-05-02",{"date":73,"type":21},"2029-08-31",{"name":46,"class":47},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":48},"100636754","effectiveness-of-stimulation-on-the-sciatic-nerve-in-aclr-100636754","NCT07569796","Effectiveness of Stimulation on the Sciatic Nerve in ACLR","\"Effectiveness of Percutaneous Electrical Nerve Stimulation on the Sciatic Nerve in Patients Undergoing Surgical Reconstruction of the Anterior Cruciate Ligament. A Randomized Clinical Trial\".","Inclusion Criteria:\n\n* Use of the Semitendinous and Gracilis tendons for ACL Reconstruction\n* Joint Range of Motion greater than or equal to 90\n* Primary ACL injury in the leg to be treated\n\nExclusion Criteria:\n\n* Chronic or rheumatic joint disease\n* Central nervous system disorder\n* Heart disease (pacemaker)\n* Neoplasms\n* Epilepsy\n* Coagulopathies (use of anticoagulants)\n* History of spinal surgery or lumbar disease\n* History of neurological disorders\n* Prosthesis or osteosynthesis in the operated leg\n* Structural discrepancy in lower-limb length\n* Belonephobia (overwhelming fear of needles)\n* Neuropathic pain or bilateral symptoms\n* Use of analgesics\n* Quadriceps tendon graft harvest\n* Body mass index \\\u003C20 or \\>30 kg\u002Fm²\n* Acute muscle injuries\n* Knee joint instability\n* Acute joint inflammation","60 Years",{"count":84,"type":21},62,[24],"After randomization, the control group will receive conventional physiotherapy, including manual therapy and therapeutic exercise for ACL rehabilitation. The first experimental group will undergo percutaneous electrical nerve stimulation of the sciatic nerve, while the second experimental group will receive a placebo stimulation. Both interventions aim to improve isometric strength, muscle activation, joint range of motion, and thigh circumference, as well as reduce pain and intra-articular effusion. The procedure involves needle insertion into the sciatic nerve epineurium, placement of a surface electrode on the hamstrings, and connection to an electrostimulator.",[88],"Anterior Cruciate Ligament Reconstruction Rehabilitation",[90,91,92,93],"PENS","ACL surgery","ACL rehabilitation","Sciatic Nerve","2026-05-04",{"date":96,"type":40},"2026-05-06",{"date":98,"type":40},"2025-12-01",{"date":100,"type":21},"2026-12",{"name":46,"class":47},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":48},"100272703","meal-timing-genetics-and-weight-loss-100272703","NCT02829619","Meal Timing, Genetics and Weight Loss","Meal Timing, Genetics and Weight Loss in a Mediterranean Population","ONTIME","Inclusion Criteria:\n\n* Body Mass Index: \\>25 kg\u002Fm2\n* Age: \\>18 years of age\n* Caucasian\n\nExclusion Criteria:\n\n* Receiving treatment with thermogenic, lipogenic, or contraceptive drugs\n* Diabetes mellitus, chronic renal failure, hepatic diseases, or cancer diagnosis\n* bulimia diagnosis, prone to binge eating\n* undergoing treatment with anxiolytic or antidepressant drugs",true,{"count":112,"type":21},5788,"OBSERVATIONAL","Meal times differ from culture to culture. These differences may influence energy regulation and, consequently, body weight. Current studies support the notion that not only \"what\" but also \"when\" the investigators eat may have a significant role in obesity treatment. Recently, it has been shown that eating the main meal of the day, lunch in Spain, late in the day is predictive of difficulty in weight loss and decreased insulin sensitivity. This project aims to study in a Mediterranean population the potential influence of genetics and food timing on obesity, metabolic syndrome and weight loss.",[116],"Obesity",[116,118,119,120],"Nutrigenetics","Food Timing","Weight loss","2026-04-29",{"date":96,"type":40},{"date":124,"type":40},"2008-01-01",{"date":126,"type":21},"2032-06",{"name":46,"class":47},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":48},"100504662","free-mucogingival-graft-for-isolated-root-coverage-100504662","NCT05851248","Free Mucogingival Graft for Isolated Root Coverage","Free Mucogingival Graft for Isolated Root Coverage and Correct Unfavorable Mucogingival Conditions in Lower Incisors: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Healthy patients with deep GR associated with lower incisor MCD.\n* Full mouth plaque and bleeding scores were \\\u003C20%.\n\nExclusion Criteria:\n\nPatient characteristics:\n\n* Smoking ≥10 cigarettes a day.\n* Medications or systemic contraindications for oral surgery.\n* Pregnancy.\n\nDefects:\n\n* Thin scalloped biotype (AND\u002FOR)\n* Underlying bone dehiscence (AND \u002FOR)\n* Generalized GR affecting most sextants.",{"count":136,"type":21},24,[24],"The goal of this clinical trial is to to describe and evaluate an approach, free mucogingival graft (FMG), in periodontal plastic surgery for root coverage (RC) in lower incisor gingival recessions (GR) with mucogingival conditions and deformities (MCD) that might negatively influence the outcomes of conventional RC procedures.",[140,141,142,143],"Free Mucogingival Grafts","Gingival Recession","Root Coverage","Periodontal Plastic Surgery","2026-02-16",{"date":146,"type":40},"2026-02-19",{"date":148,"type":40},"2023-01-02",{"date":150,"type":21},"2027-04-22",{"name":46,"class":47},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":48},"100480249","periodontal-granulation-tissue-preservation-in-surgical-periodontitis-treatment-100480249","NCT05533528","Periodontal Granulation Tissue Preservation in Surgical Periodontitis Treatment","Periodontal Granulation Tissue Preservation in Surgical Periodontal Disease Treatment. A Randomized Clinical Trial","Inclusion Criteria:\n\n* Stage III or IV periodontitis, including all grades.\n* Unresolved deep pockets (probing pocket depth \\[PPD\\] \\>5 mm + BoP) 4 to 6 weeks after non-surgical treatment.\n* Interproximal plaque index \\\u003C35% maintained during periodontal treatment and maintenance.\n* Adherence to periodontal maintenance appointments.\n\nExclusion Criteria:\n\n* Systemic disease contraindicating periodontal surgery.\n* Teeth with incorrect endodontic treatment or restoration.\n* Stage I or II periodontitis.",{"count":160,"type":21},25,[24],"The objective of this study will be to evaluate a new protocol for the surgical treatment of periodontal disease with two novelties: to make a single incision in the midline of the interproximal area to respect the vascular supply and preserve the granulation tissue with regenerative potential.\n\nThe investigators will carry out a controlled and randomized clinical trial with a control group (n=25; modified Kirkland flap) and a test group (n=25; experimental surgical protocol: incision in the mid-interproximal area of the papilla and preservation of the granulation tissue).\n\nClinical parameters will be taken at the time of surgery and 12 months follow-up: bleeding on probing (BoP), clinical attachment level (CAL), residual probing depth (rPD),Probing pocket depth reduction (PPDr), recession (REC), interproximal gingival recession (iGR), width of keratinized gingiva (KT), gain of supra-alveolar clinical attachment (SUPRA-AG), early wound healing index (EHI).",[164,31,165],"Periodontal Pocket","Periodontal Bone Loss",{"date":146,"type":40},{"date":168,"type":40},"2022-05-03",{"date":170,"type":21},"2027-02-01",{"name":46,"class":47},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":188,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":197,"locationsCount":48},"100457513","minimally-invasive-sinus-lift-through-the-interradicular-septum-100457513","NCT05237570","Minimally Invasive Sinus Lift Through the Interradicular Septum","Minimally Invasive Microsurgical Sinus-lift Through the Interradicular Septum. A Clinical Trial","Inclusion Criteria:\n\n* Patient older than 18 years.\n* Plaque index and bleeding index less than 30%.\n* Invagination of the sinus cavity in the interradicular area of the upper first molar.\n* Upper first molar not restorable and with height of the interradicular remnant less than 5 mm.\n\nExclusion Criteria:\n\n* Presence of systemic disease contraindicating the intervention.\n* Pregnant women.",{"count":180,"type":21},20,[24],"This study aims to describe a new approach for the reconstruction of the alveolar process in the sinus area. This minimally invasive approach will access the maxillary sinus through the alveolar process, elevating the sinus membrane in the area immediately above it. The regeneration may be achieved in the specific area required for dental implant placement, reducing the morbidity of the procedure.",[184,185,186,187],"Bone Loss","Bone Loss, Age-related","Atrophy; Alveolar Process","Surgical Procedure, Unspecified",[189,190,191],"maxillary sinus","sinus lift","xenograft",{"date":193,"type":40},"2026-02-17",{"date":195,"type":40},"2021-03-02",{"date":170,"type":21},{"name":46,"class":47},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":48},"100362314","non-incised-papillae-surgical-approach-nipsa-and-connective-tissue-graft-plus-emdogain-for-periodontal-defects-100362314","NCT03997578","Non-incised Papillae Surgical Approach (NIPSA) and Connective Tissue Graft Plus Emdogain for Periodontal Defects","Non-incised Papillae Surgical Approach (NIPSA) and Connective Tissue Graft Plus Enamel Matrix Derivated and Xenograft for the Treatment of Periodontal Defects: A Controlled Clinical Trial","Inclusion Criteria:\n\n* patients diagnosed with periodontitis.\n* plaque index and bleeding index of \\\u003C 30%.\n* periodontal lesions with pocket probing depth \\> 5 mm.\n* intrabony defect \\> 3 mm.\n* intrabony defect configuration including a 1 and\u002For 2-wall component, always involving the buccal wall.\n\nExclusion Criteria:\n\n* patients with systemic diseases that contraindicated treatment.\n* third molars.\n* teeth with incorrect endodontic or restorative treatment.",{"count":206,"type":21},40,[24],"The present study pretends to show the results of combining a modification of the Non-incised papillae surgical approach (NIPSA) attempting to improve the outcome in the treatment of teeth with advanced periodontal support loss.",[210,165,211],"Periodontitis","Periodontal; Lesion",{"date":146,"type":40},{"date":214,"type":40},"2019-09-03",{"date":216,"type":21},"2027-02-02",{"name":46,"class":47},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":233,"locationsCount":48},"100362312","nipsa-versus-marginal-approach-by-palatal-incision-and-mist-in-periodontal-regeneration-100362312","NCT03997552","NIPSA Versus Marginal Approach by Palatal Incision and MIST in Periodontal Regeneration","Non-Incised Papillae Surgical Approach (NIPSA) Versus Marginal Approach by Palatal Incision and Minimally Invasive Surgical Technique (MIST) in Periodontal Regeneration: a Ramdomized Clinical Trial",{"count":225,"type":21},60,[24],"Three techniques for periodontal reconstruction will be compared, in which marginal access versus apical access will be carried out.",[210,31,164],{"date":193,"type":40},{"date":231,"type":40},"2019-09-06",{"date":170,"type":21},{"name":46,"class":47},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":249,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":48},"100616811","perinatal-risk-factors-in-motor-development-100616811","NCT07310459","Perinatal Risk Factors in Motor Development","Evaluation of Perinatal Risk Factors in Future Gross Motor Development of Preterm Infants: a Cross-sectional Study","Inclusion Criteria:\n\n* preterm infants showing biological risk factors\n* parents or tutors signe an informed consent.\n\nExclusion Criteria:\n\n* Diagnosis of encephalopathy\n* genetic syndromes\n* congenital malformations\n* neuromuscular disorders\n* myopathies\n* metabolic and oncologic diseases","18 Months",{"count":243,"type":21},160,"The aim of this study is to analyze the effect of preterm gestational age, birth weight and perinatal risks factors on gross motor development of preterm infants.\n\nWe will compare the data of infants evaluated by the Alberta Infant Motor Scale (AIMS) and the Perinatal Risk Inventory (PERI) in an Infant Development and Early Intervention Center (IDEIC).",[246,247,248],"Premature Infant","Risk Factors","Motor Development of Premature Infants","NOT_YET_RECRUITING","2025-12-15",{"date":252,"type":40},"2025-12-30",{"date":254,"type":21},"2026-02-01",{"date":256,"type":21},"2026-04-30",{"name":46,"class":47},{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":48},"100548988","three-types-of-papilla-incision-in-periodontal-surgery-100548988","NCT06428149","Three Types of Papilla Incision in Periodontal Surgery","Wound Healing After Different Types of Papilla Incision in Periodontal Reconstruction Surgery. a Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients diagnosed with periodontal disease.\n* Active residual pockets associated with intraosseous defects that did not resolve with non-surgical treatment after 1 year of maintenance.\n* Intraosseous lesions with probing depth greater than 5 mm or extension of the radiographic defect greater than 4 mm.\n* Plaque index and bleeding index less than 30%.\n\nExclusion Criteria:\n\n* Systemic disease that contraindicates periodontal surgery.\n* Pregnant women.\n* Third molars or teeth with incorrect endodontic or restorative treatment.","80 Years",{"count":267,"type":21},30,[24],"Three types of papilla incision in periodontal reconstruction techniques will be compared.",[210,31,164],"2025-03-24",{"date":273,"type":40},"2025-03-28",{"date":275,"type":40},"2023-06-01",{"date":277,"type":21},"2026-12-01",{"name":46,"class":47},""]